Induction of brain-infiltrating T-bet–expressing B cells in multiple sclerosis by van Langelaar, J. (Jamie) et al.
RESEARCH ARTICLE
Induction of Brain-Inﬁltrating
T-bet–Expressing B Cells in
Multiple Sclerosis
Jamie van Langelaar ,1* Liza Rijvers,1* Malou Janssen,1,2 Annet F. Wierenga-Wolf,1
Marie-José Melief,1 Theodora A. Siepman, MD,2 Helga E. de Vries, PhD,3
Peter-Paul A. Unger,4 S. Marieke van Ham, PhD,4,5 Rogier Q. Hintzen, MD, PhD,1,2† and
Marvin M. van Luijn, PhD1
Objective: Results from anti-CD20 therapies demonstrate that B- and T-cell interaction is a major driver of multiple
sclerosis (MS). The local presence of B-cell follicle-like structures and oligoclonal bands in MS patients indicates that certain
B cells inﬁltrate the central nervous system (CNS) to mediate pathology. Which peripheral triggers underlie the develop-
ment of CNS-inﬁltrating B cells is not fully understood.
Methods: Ex vivo ﬂow cytometry was used to assess chemokine receptor proﬁles of B cells in blood, cerebrospinal
ﬂuid, meningeal, and brain tissues of MS patients (n = 10). Similar analyses were performed for distinct memory subsets in
the blood of untreated and natalizumab-treated MS patients (n = 38). To assess T-bet(CXCR3)+ B-cell differentiation, we cul-
tured B cells from MS patients (n = 21) and healthy individuals (n = 34) under T helper 1- and TLR9-inducing conditions.
Their CNS transmigration capacity was conﬁrmed using brain endothelial monolayers.
Results: CXC chemokine receptor 3 (CXCR3)-expressing B cells were enriched in different CNS compartments of MS
patients. Treatment with the clinically effective drug natalizumab prevented the recruitment of CXCR3high IgG1+ sub-
sets, corresponding to their increased ability to cross CNS barriers in vitro. Blocking of interferon-γ (IFNγ) reduced the
transmigration potential and antigen-presenting function of these cells. IFNγ-induced B cells from MS patients showed
increased T-bet expression and plasmablast development. Additional TLR9 triggering further upregulated T-bet and
CXCR3, and was essential for IgG1 switching.
Interpretation: This study demonstrates that T-bethigh IgG1+ B cells are triggered by IFNγ and TLR9 signals, likely con-
tributing to enhanced CXCR3-mediated recruitment and local reactivity in the CNS of MS patients.
ANN NEUROL 2019;86:264–278
B cells are one of the main contributors to chronic auto-immune pathology in multiple sclerosis (MS), as
supported by results from large genome-wide association
studies.1 B-cell repertoires in the central nervous system
(CNS) and the periphery are closely connected, suggesting
that disease-relevant B-cell networks interact at both sides
of the blood–brain barrier.2–5 There is evidence that the
beneﬁcial effects of anti-CD20 monoclonal antibody therapy
are related to the ablation of functional B cells interacting
with T cells.6,7 The meninges of MS patients contain tertiary
lymphoid structures that are ﬁlled with B and T cells, close
to cortical lesions.8 This strongly suggests that B- and T-cell
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interaction is a major event in triggering and sustaining
inﬂammation in the CNS.
In MS, autoreactive (naive) B cells escape peripheral
selection and probably receive speciﬁc signals from CD4+
T cells within secondary lymphoid organs to differentiate
into memory populations before entering the CNS.5,9,10
The presence of oligoclonal bands (OCBs) in the cerebrospi-
nal ﬂuid (CSF) of MS patients implies that these memory B
cells undergo local reactivation (with the help of CD4+ T
cells) to further develop into immunoglobulin (Ig)-producing
plasmablasts and plasma cells.8,11 Although memory B cells
have been recently shown to promote the differentiation of
CNS-inﬁltrating CD4+ T cells in MS, little is known about
how and which functional B-cell subsets are triggered in the
periphery to inﬁltrate the CNS and contribute to MS
pathology.
In mice, the T helper 1 (Th1) cytokine interferon-γ
(IFNγ) induces the interaction between autoreactive B cells
and CD4+ T cells to form tertiary lymphoid structures and
promote systemic autoimmune diseases such as systemic
lupus erythematosus (SLE).12 In these cases, IFNγ induces
the expression of the T-box transcription factor T-bet,
resulting in enhanced Ig class switching and CXC chemokine
receptor 3 (CXCR3) expression in murine B cells.13,14 Inter-
estingly, B-cell–intrinsic T-bet expression associates with
increased pathogenic responses14,15 and is induced by sys-
temic infections,16 a major environmental trigger in MS.17
Toll-like receptor 9 (TLR9), which binds to pathogen-related
CpG-DNA, integrates with the B-cell receptor (BCR),
CD40, and cytokine signals to stimulate T-bet+ B-cell devel-
opment.18,19 Additionally, B cells from MS patients were
previously reported to exhibit an enhanced proinﬂammatory
phenotype when activated with IFNγ and TLR9 ligand
CpG-DNA.7
Here, we aimed to explore the CNS transmigration
capacity of T-bet(CXCR3)-expressing B cells and which
peripheral triggers are involved in the development of such
populations in MS patients. We explored the recruitment
of human CXCR3+ B cells to the CNS both ex vivo and
in vitro. Furthermore, the susceptibility of blood-derived B
cells from MS patients and healthy individuals to T-bet–
inducing stimuli and how this inﬂuences their differentia-
tion into CXCR3+ memory subsets was determined using
different T-cell–based culture systems.
Subjects and Methods
Patients
Postmortem CSF, meninges, brain tissues, and blood samples were
freshly obtained from MS brain donors (Netherlands Brain Bank,
Amsterdam, the Netherlands). The main cause of death was legally
granted euthanasia (8 of 10 donors). The 2 other donors died from
pneumonia or MS. These tissues had a very short postmortem delay
of 8.92 hours (interquartile range [IQR] = 8.50 – 9.50 hours), and
pH of the CSF was 6.59 (IQR = 6.44–6.87). All other MS patients
and healthy controls were included at Erasmus Medical Center
(Rotterdam, the Netherlands), which is a national tertiary
referral center for MS patients (Multiple Sclerosis Center
ErasMS). Patients and controls were age- and gender-matched
per study group. Patient characteristics are summarized in
Table 1. Primary material was obtained between 2007 and
2018. All patients gave written informed consent, and study
protocols were approved by the medical ethics committee of
the Erasmus Medical Center (Rotterdam) and VU University
Medical Center (Amsterdam, the Netherlands).
Mononuclear Cell Isolation from Blood and CNS
Compartments
Peripheral blood mononuclear cells (PBMCs) were isolated
according to the manufacturer’s instructions from blood of MS
patients and matched controls with the use of vacutainer CPT®
tubes containing sodium heparin (BD Biosciences, Erembodegem,
Belgium). PBMCs were frozen and stored in liquid nitrogen until
use as previously described.20 Mononuclear cells were isolated
from buffy coats using Ficoll-Paque Plus (GE Healthcare, Frei-
burg, Germany) and density gradient centrifugation. Blood and
CSF samples from MS brain donors were acquired postmortem
through heart puncture and ventricle drainage, respectively.20
Heart blood mononuclear cells were isolated as described for buffy
coat material. Collection tubes with CSF were centrifuged for
10 minutes at 500 × g. CSF and blood mononuclear cell fractions
were resuspended in RPMI 1640 (Lonza, Verviers, Belgium) con-
taining 10% heat-inactivated human AB serum (Sanquin, Rotter-
dam, the Netherlands) and 1% penicillin/streptomycin (Lonza)
and left to rest at 37C until further use. Meninges were washed
in phosphate-buffered saline (PBS) containing 0.1% bovine serum
albumin (BSA) 3 times, cut into pieces, and incubated with
Liberase (Roche Applied Science, Penzberg, Germany) for 1 hour
at 37C, after which the meninges were ﬁltered through a cell
strainer (45μm) and cells were washed using Ficoll-Paque Plus
(GE Healthcare). Single-cell suspensions from the meninges were
resuspended in PBS containing 0.1% BSA until further use. Brain
tissue samples were processed and single-cell suspensions were
obtained as previously reported.21
Antibodies and Flow Cytometry
Multicolor ﬂow cytometric analysis was performed using
ﬂuorochrome-labeled monoclonal anti-human antibodies (mAbs;
Table 2). PBMCs were stained extracellularly for 30 minutes at
4C. Cultured B cells were stained with a ﬁxable viability stain
(FVS 700) for 15 minutes at 4C and subsequently stained for
either extracellular only or both extracellular and intracellular
markers. For intracellular staining, cells were ﬁxed with 2%
paraformaldehyde (Merck, Schiphol-Rijk, the Netherlands) and
permeabilized with PBS pH7.4 containing 0.3% BSA and
0.5% saponin (Sigma-Aldrich, St Louis, MO) and stained with
T-bet for 60 minutes at 4C. All measurements were conducted
with an LSRII-Fortessa ﬂow cytometer and analyzed using
FACS Diva software, version 8.0.1 (both BD Biosciences).
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Ex vivo Th17.1 (IFNγhighIL-17low) and Th17 (IFNγneg) cells
in blood were deﬁned as CCR6+CXCR3+CCR4− (Th17.1) and
CCR6+CXCR3−CCR4+ (Th17), described recently.20
Human B-Cell Migration Assays
Flow-activated cell sorting (FACS)-sorted CD27− and CD27+
memory CD19+ B cells from buffy coat–derived PBMCs were
placed on 96 permeable transwell plates with a 0.3μm pore size
(2 × 105 cells/well; Corning, Amsterdam, the Netherlands).
B-cell migration toward medium or CXC chemokine ligand
(CXCL)10 (900ng/ml; R&D Systems, Abingdon, UK) was ana-
lyzed after 3 hours at 37C. In addition, 2.5–5 × 105 memory
B cells were placed on conﬂuent monolayers of human brain
endothelial cells (hCMEC/D3) on 5μm pore size transwell plates
(Corning) coated with collagen, and migration was analyzed after
5 hours.22 Percentages of memory B-cell subsets were compared
before and after transmigration using ﬂow cytometry.
Antigen-Primed Autologous B- and Th-Cell
Cocultures
BCR-mediated uptake and presentation of Salmonella typhimurium
SL1344 was used as a model for antigen presentation, as previously
demonstrated.23 mAb anti-human IgG (MH16-1; Sanquin,
Amsterdam, the Netherlands) was mixed with mAb against
S. typhimurium lipopolysaccharide (LPS; 1E6; Invitrogen, Paisley,
UK) and rat anti-mouse IgG1 antibody (RM161.1, Sanquin) to
generate BCR-LPS tetrameric antibody complexes. Exponentially
grown bacteria were washed twice with PBS, incubated with BCR-
LPS tetrameric antibody complexes for 30 minutes at room temper-
ature, and washed twice to remove unbound antibodies. B cells
were incubated with viable anti-IgG–coated S. typhimurium23 at
20 bacteria per cell for 45 minutes at 37C without antibiotics.
Next, cells were washed 3 times and cultured for 60 minutes in
medium containing 100μg/ml gentamicin (Invitrogen) to eliminate
nonphagocytosed bacteria. B cells were cocultured in RPMI sup-
plemented with 5% fetal calf serum, 1% (100U/ml) penicillin, 1%
(100μg/ml) streptomycin (Lonza), 1% (2mM) UltraGlutamine
(Lonza), 0.1% (50μM) beta-mercaptoethanol (Sigma-Aldrich),
0.1% (20μg/ml) apotransferrin (depleted for human IgG with
protein-G sepharose; Sigma-Aldrich; further referred to as B-cell
medium), and 10μg/ml gentamicin together with autologous CD4+
T cells (magnetic activated cell sorted). B cells (1 × 105) and T cells
(0.5 × 105) were cultured in 200μl at 37C in the presence of 5%
TABLE 1. Characteristics of Patients and Controls Used in This Study
Cohorts Subject,
n
Gender,
Female, n (%)
Age, Median
yr (IQR)a
Disease Duration,
Median mo (IQR)b
Ex vivo B cells, CNS vs blood
MS 10 9 (90%) 52 (50–65) NA
Ex vivo B cells, blood subsets
HC 10 7 (70%) 47 (32–54) NA
MS, no Tx 10 7 (70%) 45 (43–53) 48 (24–120)
MS, NAT Tx
First cohort 10 7 (70%) 40 (29–46)c 90 (31–124)
Second cohort 9 6 (66%) 36 (26–43)c 46 (41–130)
Third cohortd 9 5 (56%) 28 (21–43)c 28 (19–41)
In vitro–stimulated B cells
HC
Total 10 8 (80%) 44 (32–56) NA
Naive 8 5 (63%) 39 (27–50) NA
MS, no Tx
Total 9 7 (80%) 41 (34–56) 36 (36–73)
Naive 12 8 (67%) 38 (28–42) 4 (3–15)
aAt time of sampling.
bTime from MS diagnosis to sampling.
cAt time of pretreatment sampling.
dIgG subclass instead of total IgG analysis.
CNS = central nervous system; HC = healthy controls; IQR = interquartile range; MS = multiple sclerosis; NA = not applicable; NAT = natalizumab;
Tx = treatment.
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CO2 in 96-well round-bottom plates (Greiner Bio-One, Alphen
aan den Rijn, the Netherlands) for 6 days. Cultures were performed
in the presence of recombinant interleukin (IL)-21 (50ng/ml;
Thermo Fisher Scientiﬁc, Landsmeer, the Netherlands) and
recombinant IL-2 (50IU/ml, Miltenyi Biotec, Bergisch Gladbach,
Germany), and with or without an anti-IFNγ blocking anti-
body (MD-1, 10μg/ml; U-CyTech Biosciences, Utrecht, the
Netherlands).
IL-21/3T3-CD40L Assay for Human B-Cell
Differentiation
To mimic B-cell differentiation in vitro, murine NIH3T3 ﬁbroblasts
expressing human CD40L (3T3-CD40L)23 were irradiated at 30Gy
using a RS320 X-ray (Beckhoff, Eindhoven, the Netherlands), taken
up in B-cell medium, and seeded on ﬂat-bottom 96-well plates
(10 × 103 cells per well; Greiner Bio-One) to allow adherence over-
night. CD19+ (total) B cells were isolated from buffy coat–derived
PBMCs using CD19 microbeads and the autoMACS Pro Separator
(both Miltenyi Biotec). Total, naive (CD38−/dimCD27−IgG−IgA−)
and memory (CD38−/dimCD27+IgG+) B cells were isolated from
healthy andMS blood using a BDFACSAria III cell sorter. These frac-
tions were resuspended in B-cell medium, and 20–25 × 103 cells were
cocultured with irradiated 3T3-CD40L cells and stimulated with a
combination of IL-21 (50ng/ml; Thermo Fisher Scientiﬁc), IFNγ
(50ng/ml; Peprotech/Bio-Connect, Huissen, the Netherlands), and
CpG-ODN (2006-G5; 10μg/ml; InvivoGen/Bio-Connect) at 37C
and 5% CO2. After 6 and 11 days of culture, supernatants were col-
lected and stored at −80C until use for enzyme-linked immunosor-
bent assay (ELISA). The cells were stained and assessed using ﬂow
cytometry as described above.
IgG1 ELISA
Nunc MaxiSorp plates (Sanbio, Uden, the Netherlands) were
coated overnight with antihuman IgG1 monoclonal capture anti-
body (1μg/ml; clone MH161-1; Sanquin, Amsterdam, the Neth-
erlands) in PBS. After washing with PBS–0.02% Tween-20, the
supernatants from in vitro B-cell cultures (described above) were
diluted in high-performance ELISA buffer (HPE, Sanquin) and
incubated for 60 minutes. Subsequently, plates were washed and
incubated for 60 minutes with anti-human IgG conjugated with
horseradish peroxidase, a monoclonal detection antibody (1μg/ml;
clone MH16-1, Sanquin). After washing, the ELISA was devel-
oped with MQ containing 0.11M sodium-acetate (pH 5.5),
100μg/ml tetramethylbenzidine, and 0.003% (vol/vol) H2O2 (all
from Merck). The reaction was stopped by addition of 2M
H2SO4 (Merck). Optical densities at 450nm were measured with
a BioTek (Winooski, VT) Synergy 2. Background readings at
540nm were subtracted. Results were related to a titration curve
of a serum sample of a healthy donor in each plate.
Statistical Analyses
All datasets were analyzed with GraphPad Prism Software, ver-
sion 7 (GraphPad Software, San Diego, CA) and compared using
2-sided Mann–Whitney U tests, Wilcoxon matched-pairs signed
rank test, 1- or 2-way analysis of variance with Tukey post hoc
TABLE 2. Monoclonal Antihuman Antibodies Used
for Flow-Activated Cell Sorting
Antibody
Marker
Fluorochrome Clone Company
CD3 AF700 SK7 BioLegenda
CD3 BV785 SK7 BD
Biosciencesb
CD4 BV510 OKT4 BioLegend
CD19 BV785 HIB19 BD
Biosciences
CD20 AF700 2H7 BD
Biosciences
CD21 BV711 B-Ly4 BD
Biosciences
CD27 BV421 M-T271 BD
Biosciences
CD38 PE-Cy7 and
PerCP-Cy5.5
HIT2 BioLegend
CD49d
(VLA-4)
APC 9F10 BD
Biosciences
CCR4 PE-Cy7 L291H4 BioLegend
CCR6 PE G024E3 BioLegend
CXCR3 BV605 and
APC
G025H7 BioLegend
CXCR5 APC-R700 RF8B2 BD
Biosciences
IgA FITC IS11-8E10 Miltenyi
Biotechc
IgD PE and PE-
CF594
IA6-2 BD
Biosciences
IgG ACP-H7 G18-145 BD
Biosciences
IgG1 PE HP6001 Southern
Biotechd
IgG2 AF488 HP6002 Southern
Biotech
IgM BV510 MHM-88 BioLegend
T-bet PE-Cy7 4B10 BioLegend
Fixable
viability
dye (FVS)
AF700 BD
Biosciences
aBioLegend, London, UK.
bBD Biosciences, Erembodegem, Belgium.
cMiltenyi Biotech, Leiden, the Netherlands.
dSouthern Biotech via ITK Diagnostics, Uithoorn, the Netherlands.
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test, Friedman paired test with Dunn post hoc test, and Spearman
correlation coefﬁcients (as indicated in each ﬁgure legend). Experi-
mental data are depicted as the mean  standard error of the
mean. Prior to statistical analyses, datasets were tested for normal
distribution. Probability values <0.05 were considered signiﬁcant.
Results
CXCR3-Expressing B Cells Are Selectively
Enriched in Distinct CNS Compartments of MS
Patients
Enhanced chemotaxis is one of the key mechanisms by
which B cells can enter distinct CNS compartments of MS
patients.11 Production of the chemoattractants CXCL10,
CXCL13, and CCL20 in the CNS has been associated
with B-cell recruitment, distribution, and reactivity in
MS.24–26 We compared the presence of B cells that express
the chemokine receptors that correspond to these ligands,
CXCR3+ (CXCL10), CXCR5+ (CXCL13), and CCR6+
(CCL20), between paired blood, CSF, and meningeal and
brain tissues from 10 MS patients (see Table 1). To realize
this, single-cell suspensions were obtained from autopsied
brain compartments using a standardized protocol.21 From
these fractions, viable CD45+CD3−CD19+ B cells were
gated and analyzed for chemokine receptor expression using
ﬂow cytometry (Fig 1A). We were able to measure sufﬁ-
cient numbers of viable B cells from each compartment for
all donors (mean [range]: blood, 21,509 [610–98,562];
CSF, 12,629 [50–59,499]; meninges, 13,819 [91–36,644];
brain tissue, 2,889 [26–18,050]). The frequency of CXCR3+
but not CXCR5+ or CCR6+ B cells was strongly increased in
ex vivo cell suspensions from MS brain tissues (p < 0.0001),
meninges (p = 0.0003), and CSF (p < 0.0001) compared to
blood (See Fig 1B). CXCR3-expressing T cells, including
Th17.1, were also enriched in the CNS compartments of
these donors (data not shown), supporting our recent
observations.20
Reduced Frequencies of CXCR3+IgG(1)+ B Cells
in the Blood of MS Patients Are Abrogated after
Natalizumab Treatment
To determine how CXCR3 is involved in the local attrac-
tion of different B-cell populations in MS, we assessed the
proportion of CXCR3-expressing naive (CD27−IgM+;
IgMnaive) and both IgM
+ memory (CD27+IgM+; IgMmem)
and IgG+ memory (CD27+IgG+) B cells in the peripheral
blood of untreated MS patients (n = 10) and age- and
gender-matched healthy controls (HCs; n = 10; see Table 1
and Fig 2A). CXCR3-expressing IgG+ cells were reduced
(p = 0.007), whereas no differences were seen for IgMnaive
and IgMmem cells in MS versus HC blood (See Fig 2B).
To address this potential migration of CXCR3+IgG+
memory B cells into the CNS, we analyzed the distribution
of these B-cell subsets in the blood of MS patients treated
with the anti-α4β1 integrin (VLA-4) antibody natalizumab
(see Table 1), a drug that effectively reduces MS disease
activity by blocking lymphocyte recruitment to the CNS.27
VLA-4 was most abundantly expressed on blood IgG+ B
cells from MS patients prior to natalizumab treatment (see
Fig 2). Elevated frequencies of both IgMmem (pretreatment
vs 6 months post-treatment p = 0.042 and 12 months
post-treatment p = 0.011) and IgG+ (pretreatment vs
6 months post-treatment p = 0.022 and 12 months post-
treatment p < 0.001) B cells were found in the blood of
MS patients both 6 and 12 months after versus before
treatment. However, only IgG+ and not IgMnaive or
IgMmem B cells from MS patients treated with natalizumab
for 12 months showed increased expression levels of
CXCR3 (p < 0.01), and not CXCR5 or CCR6. These ﬁnd-
ings were validated in a second cohort of 9 MS patients
treated with natalizumab (see Table 1; data not shown).
Notably, CD20 expression levels were increased on IgG+ B
cells and higher on CXCR3+ compared to CXCR3− coun-
terparts in the blood of natalizumab-treated MS patients.
Because intrathecally synthesized OCBs are restricted
to the IgG1 subclass in the CSF ofMS patients,28 we also ana-
lyzed IgG1+ B cells for their frequencies and CXCR3 expres-
sion in the blood of a third cohort of natalizumab-treated MS
patients (see Fig 2). IgG1+ B cells not only expressed higher
levels of CXCR3 (p = 0.007) but also showed increased fre-
quencies in post-treatment samples (p = 0.027) compared
to IgG2+ B cells. The selective accumulation of CXCR3high
IgG(1)+ B cells in the blood of natalizumab-treated patients
underlines the potency of this subset to transmigrate into the
CNS tomediateMS disease activity.
CXCR3+IgG1+ B Cells Have an Enhanced
Capacity to Transmigrate Across the Blood–
Brain Barrier In Vitro
To functionally test the transmigration potential of
CXCR3+IgG1+ B cells into the CNS, we sorted memory
B cells from the blood and assessed in vitro migration of
subsets toward CXCL10. Fractions of CXCR3-expressing
IgMmem, IgG1
+, and IgG2+ B cells were assessed within the
total memory pool before and after migration through
transwell ﬁlters. In contrast to IgMmem and IgG2
+
populations, IgG1+ B cells showed prominent recruitment
to CXCL10 (p < 0.0001 before vs after migration; Fig 3).
This was not seen using medium only. To mimic B-cell
transmigration across the blood–CNS barrier, these experi-
ments were repeated using cultured conﬂuent monolayers
of human brain endothelial cells.22 We found a similar
CXCL10-mediated migratory advantage of IgG1+ B cells
(p < 0.0001), which is consistent with the abundance of
CXCR3 on IgG1+ compared to IgMmem and IgG2
+ B cells
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in MS patients (see Fig 2G–I). These data demonstrate that
CXCR3high IgG1+ B cells in the blood have a heightened
ability to inﬁltrate the CNS, probably accounting for the
local IgG1 subclass restriction of OCBs in MS patients.28
IFNγ Promotes CXCR3 Expression and CD4+ T-
Cell Activation by Human T-bet+ B Cells under T
Follicular Helper–like Culture Conditions
In MS blood, the proportion of CXCR3+IgG+ B cells corre-
lated to Th17.1 (IFNγhighIL-17low; r = 0.566, p = 0.0003)
and not to Th17 (IFNγneg) cells (Fig 4).20 Th-cell–derived
IFNγ is known as a central driver of autoreactive B cells in
mice10 and also induces CXCR3 expression on human
memory B cells.29 Therefore, we aimed to better understand
how the differentiation and function of human CXCR3+
memory B cells is inﬂuenced by IFNγ before entering the
CNS. To address this, we mimicked the effects of IFNγ-
producing T follicular helper (Tfh) cells on B-cell subsets
in vitro. First, an IL-21–based human B- and T-cell
coculture system was used to assess whether Th1-derived
IFNγ inﬂuenced CXCR3 expression on IgG+ B cells in an
antigen-speciﬁc manner. Because antigen uptake by B cells is
A B
FIGURE 1: CXCR3+ B cells are abundant in the central nervous system compared to blood of multiple sclerosis (MS) patients.
(A) Representative ﬂow-activated cell sorting (FACS) plots and gating of CXCR3-expressing CD19+ B cells within viable
CD45+CD3− lymphocyte fractions derived from the blood, cerebrospinal ﬂuid (CSF), meninges, and brain tissue of an MS patient.
(B) Frequencies of CXCR3+, CXCR5+, and CCR6+ B cells in distinct paired compartments from MS patients. For blood, CSF, and
meningeal samples each dot represents a different patient. A total of 10 brain tissues from 7 different MS patients were used
for the analysis of CXCR3+ B cells. Any samples with <25 viable B cells were excluded from these analyses. Data are presented
as the mean  standard error of the mean. *p < 0.05, ***p < 0.001, ****p < 0.0001. The p values for B were calculated by a
1-way analysis of variance test. LD = live/dead (for detection of viable cells).
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FIGURE 2: Reduced frequencies and natalizumab-mediated accumulation of CXCR3+IgG(1)+ B cells in multiple sclerosis
(MS) blood. (A) FACS gating strategy used to deﬁne IgMnaive (CD27
−IgM+), IgMmem (CD27
+IgM+), and IgG+ (CD27+IgG+) B-cell
subsets. (B) Gating and quantiﬁcation of CXCR3-expressing IgMnaive, IgMmem, and IgG
+ B-cell frequencies in the blood of
untreated MS patients (n = 10; dark blue dots) and both age- and gender-matched healthy controls (HC; n = 10; gray dots, see
Table 1). (C) VLA-4 surface expression on IgMnaive, IgMmem, and IgG
+ B cells from blood of MS patients before natalizumab
treatment (n = 9). (D) The percentage of IgMnaive, IgMmem, and IgG
+ B cells in MS blood before (black dots) and both 6 months
(marine blue dots) and 12 months (light blue dots) after natalizumab treatment (paired samples; n = 10; see Table 1). (E, F)
Surface expression levels of CXCR3 (E), CXCR5 and CCR6 (F) on IgMnaive, IgMmem, and IgG
+ B cells in MS patient blood before
and after natalizumab treatment (n = 7–10). (G) CD20 expression on IgMnaive, IgMmem, and IgG
+ B cells as well as paired CXCR3−
and CXCR3+ IgG+ populations in blood of MS patients treated with natalizumab for 12 months (n = 8). (H–J) Gating example and
quantiﬁcations of IgG1+ and IgG2+ B cells expressing CXCR3 in MS patients treated with natalizumab for 12 months (n = 9). Data
are presented as the mean  standard error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. The p values
were calculated by Mann–Whitney U (B), 2-way analysis of variance (C, G), Friedman paired (D–F), and Wilcoxon matched-pairs
signed rank (G, I, and J) tests. MFI = mean ﬂuorescence intensity; Tx = treatment; LD = live/dead (for detection of viable cells).
limited by the selectivity of the BCR, surface IgG was
crosslinked with Th1-associated pathogen S. typhimurium
for efﬁcient internalization, processing, and presentation
to autologous Th cells.23,30 After 6 days of coculture, we
found that the induced expression of CXCR3 on
Salmonella-containing IgG+ and not IgMnaive or IgMmem
B cells was abrogated by the addition of an IFNγ-blocking
antibody (p < 0.0001). Furthermore, blocking of IFNγ
A
B C
FIGURE 3: Enhanced migration of CXCR3+IgG1+ B cells across transwell ﬁlters and human brain endothelial monolayers in vitro. Sorted
memory B cells from healthy donor blood were assessed for selective in vitro transmigration toward CXCL10. (A) Representative FACS
plots and (B, C) quantiﬁcations of viable CXCR3-expressing IgMmem, IgG1
+ and IgG2+ B cells migrating across transwell ﬁlters with and
without conﬂuent monolayers of human brain endothelial cells (BEC). Percentages of subsets within the total memory pool were
compared before and after migration, both to medium and to CXCL10 (−BEC, n = 8; +BEC, n = 6). These experiments were performed
in duplicate for each donor for which the average is shown. Data are presented as the mean  standard error of the mean. *p < 0.05,
**p < 0.01, ****p < 0.0001. The p values were calculated by 2-way analysis of variance (B, C).
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impaired B-cell–induced T-cell proliferation, activation, and
effector memory formation. This implies that IFNγ additionally
stimulates the antigen-presenting function of CXCR3+IgG+ B
cells, in parallel with previous ﬁndings inmice.31
CXCR3 expression is under the direct control of
IFNγ-inducible transcription factor T-bet, a critical regulator
of memory B-cell differentiation in mice.13,14 Consistent
with this, intracellular T-bet positively correlated to
A
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FIGURE 4: T helper (Th) 1 cytokine interferon-γ (IFNγ) is a major trigger of CXCR3+(T-bet+) B-cell differentiation in multiple
sclerosis (MS). (A) Correlation of ex vivo CXCR3+IgG+ B cells with Th17.1 (IFNγhighIL-17low) and Th17 (IFNγneg) cells in MS blood
before and after natalizumab treatment (pre-Tx and post-Tx; n = 12). (B) Experimental model of Salmonella-primed autologous
B- and T-cell cocultures. (C–E) B cells from healthy donor blood were primed with S. typhimurium through B-cell receptor
(BCR) crosslinking using a tetrameric antibody complex, as described in Subjects and Methods. This allows BCR-mediated
Salmonella uptake, processing, and presentation on MHC II molecules to Th cells. IL-21 was added with and without an IFNγ
blocking antibody to analyze the effects on CXCR3 expression by B cells (C), and on the proliferation, activation, and effector
memory (EM) phenotype of Th cells (D, E). These experiments were performed in 2 independent experiments and in duplicate
for (C) 4 and (D, E) 2 different blood donors. (F) Correlation of surface CXCR3 and intracellular T-bet expression in ex vivo B
cells of MS patients before and after natalizumab treatment (pre-Tx and post-Tx; n = 9). (G, H) Total B cells from the blood of
MS patients (n = 9) and both age- and gender-matched healthy controls (HC; n = 10) were cultured in vitro under T follicular
helper (Tfh)-like conditions with IL-21 and 3T3-CD40L cells, and with or without IFNγ for 11 days. Representative FACS plots
and quantiﬁcation of in vitro–induced T-bet+ B cells (G) and correlation of CXCR3 and T-bet expression in these cultured B
cells (H) are shown. Data are presented as the mean  standard error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001. The p values were calculated by 2-way analysis of variance (ANOVA; C), 1-way ANOVA (D, E), and Wilcoxon
matched-pairs signed rank (G) tests. The correlation coefﬁcients and p values for A, F, H were calculated by Spearman rank.
m = months; MFI = mean ﬂuorescence intensity; TCR = T-cell receptor.
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surface CXCR3 expression in ex vivo B cells (r = 0.644,
p = 0.0003) and showed a similar association with
Th17.1 (IFNγhighIL-17low) cells in MS patients (see Fig 4
and data not shown).20 To further explore the suscepti-
bility of B cells to IFNγ in MS,7 we compared B cells
from MS and matched healthy control blood for IFNγ-
mediated T-bet induction under Tfh-like culture con-
ditions. After 11 days of stimulation with 3T3-CD40L
cells, IL-21, and IFNγ, T-bet was predominantly upregulated
in B cells of MS patients (p = 0.021), whereas conditions
without IFNγ did not show this. This in vitro–induced T-
bet was coexpressed with surface CXCR3 (r = 0.766,
p = 0.0001), in line with our ex vivo results. These ﬁndings
reveal that Th-cell–derived IFNγ is a major trigger of
peripheral CXCR3(T-bet)+ B cells in MS.
IFNγ Stimulates Plasmablast Formation and
Synergizes with CpG-DNA to Establish IgG1
Switching during Human Tfh-like B-Cell Cultures
Besides IFNγ, TLR9 ligand CpG-DNA has also been
reported to induce T-bet in murine B cells14,18 and pro-
mote proinﬂammatory cytokine responses of B cells
from MS patients.7 To assess how TLR9 signals inte-
grate with IFNγ to regulate human T-bet+ B-cell devel-
opment, we ﬁrst determined whether naive or memory
B cells are more prone to this type of coactivation.
Naive (CD27−IgG−) and memory (CD27+IgG+) B cells
were sorted from healthy donor blood and stimulated
with 3T3-CD40L cells, IL-21, IFNγ, and/or CpG-
DNA. After 11 days of naive B-cell cultures, both
T-bet and CXCR3 expression was induced by IFNγ,
and further enhanced after addition of both IFNγ and
CpG-DNA (p = 0.001 and p = 0.021; Fig 5A). This
additional effect of CpG-DNA was not found when
using sorted memory B cells (see Fig 5B). Both IFNγ-
induced and CpG-DNA–induced T-bet(CXCR3)+ B cells
also showed strongly reduced CD21 expression (data not
shown), a typical feature seen for T-bet–expressing B cells.31
During a germinal center response, naive B cells can
either differentiate into plasmablast or memory populations,
depending on the local inﬂammatory environment.10,32
We investigated the effects of IFNγ and CpG-DNA on
plasmablast formation and IgG subclass switching during IL-
21–/CD40L-induced naive B-cell differentiation. After
11 days of culture, sorted naive B cells from healthy donors
developed into plasmablasts under IFNγ stimulatory condi-
tions only (p = 0.034; Fig 5). IFNγ and CpG-DNA together
did not induce plasmablast formation, but instead triggered
IgG1 and not IgG2 expression on differentiating B cells
(IFNγ only vs IFNγ + CpG-DNA: p = 0.002). Interest-
ingly, this in vitro-induced IgG1 switching was subjected
to differentiation of sorted naive and not memory (data
not shown) B cells. CpG-DNA alone did not upregulate
CXCR3, T-bet, and IgG1 in differentiating naive B cells
(data not shown), indicating that both IFNγ and TLR9
signaling are required for enhanced expression of these
markers. To verify that B-cell intrinsic expression also
corresponds with secretion of IgG1, we performed ELISAs
on culture supernatants of these B cells. The percentage
of IgG1+ B cells positively correlated to IgG1 secretion
(r = 0.640, p = 0.016).
Finally, to address how this is regulated in MS, we iso-
lated naive B cells from MS patients and performed similar
culture experiments. IFNγ-mediated plasmablast formation
was more induced after 11 days of culture compared to mat-
ched controls (p = 0.031; see Fig 5F). This was not seen
after stimulation with both IFNγ and CpG-DNA.
Instead, this type of triggering resulted in a robust induc-
tion of CXCR3+IgG1+, and not CXCR3+IgG2+ subsets
in MS (see Fig 5G, H). Collectively, these data demonstrate
that TLR9 signaling potentiates IFNγ-induced T-bet and
CXCR3 expression during naive B-cell differentiation in vitro,
and that this is important for IFNγ-mediated formation of
IgG1+ memory B cells rather than plasmablasts under Tfh-like
circumstances in MS.
Discussion
Evidence has accumulated that at least in the periphery,
antibody-independent roles of B cells are driving the pathol-
ogy of MS.7 However, local production of autoantibodies
should not be ruled out as an underlying B-cell mechanism
in this disease.33 Although autoreactive naive B cells are
highly active in MS blood,9 the vast majority of B cells iden-
tiﬁed in the MS brain have undergone further maturation
into antibody-producing cells.34,35 It has also been demon-
strated that memory B cells of MS patients are the most
potent antigen-presenting cells and likely have speciﬁc
proinﬂammatory propensities, including the capacity to
express enhanced levels of immune-activating molecules.35 This
is of special interest considering the presence of meningeal
B-cell–rich follicle-like structures in MS and adjacent subpial
cortical demyelinating injury,8 which probably contributes to
progressive loss of neurological function in patients with
MS. Thus, identiﬁcation of the particular B-cell subsets
that can preferentially migrate into the CNS and clariﬁcation
of how they may contribute to propagating local injury
responses are of considerable interest in such an organ-speciﬁc
disease. In this study, we demonstrate that integrating IFNγ
and pathogen-associated TLR9 signals is critical for the devel-
opment of human T-bet+ memory B cells, probably underly-
ing their selective recruitment to the CNS ofMS patients.
Recent studies have shown that in MS identical
B-cell clones are present in both the periphery and CNS.2–4
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FIGURE 5: Interferon-γ (IFNγ) induces plasmablast differentiation, whereas both IFNγ and CpG-DNA further upregulate T-bet
and trigger IgG1 switching in B cells of multiple sclerosis (MS) patients. (A–D) Naive (IgG−CD27−; dots) and memory (IgG+CD27+;
squares) B cells were sorted from peripheral blood of healthy donors and were cultured under T follicular helper (Tfh)-like
conditions with IL-21 and 3T3-CD40L cells, with or without IFNγ and/or CpG-DNA. Frequencies of T-bet+ and CXCR3+ B cells
after 11 days of culture using (A) naive B cells (n = 12) and 6 days of culture using (B) memory B cells (n = 10–12) are shown. The
frequencies of (C) plasmablasts (CD38highCD27+; n = 12) and (D) membrane-bound (m) mIgG1+ and mIgG2+ B cells were
analyzed after culturing naive populations for 11 days (n = 12). (E) Correlation between cellular expression and secretion of IgG1
was determined by FACS and enzyme-linked immunosorbent assay (pooled stimulation conditions for 5 donors). (F–H) Naive B
cells from the blood of MS patients (n = 6; dark blue dots) and healthy controls (HC; n = 6; gray dots) were cultured under the
same Tfh-like conditions and analyzed for (F) plasmablast (CD38highCD27+) and (G, H) CXCR3+mIgG1+ and CXCR3+mIgG2+ B-cell
differentiation after 11 days of culture. Data are presented as the mean  standard error of the mean. *p < 0.05, **p < 0.01,
***p < 0.001. The p values for A–D and F–H were calculated by the Wilcoxon matched-pairs signed rank test. The correlation
coefﬁcient and p value for E were calculated by Spearman rank correlation.
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That these B-cell populations further undergo somatic hyper-
mutation in the brain implies the presence of functional ger-
minal centers within the CNS. Such structures have been
identiﬁed in the meninges of MS patients and are obvious
localizations that play a role here.8 The enrichment that
we observe of CXCR3+ B cells in paired CSF, meninges,
and brain tissue compartments compared to blood of MS
patients is in line with studies that show higher levels of
CXCR3 ligand CXCL10 in the CSF of MS patients.24 These
results are also consistent with our previous ﬁndings that
CXCR3+ T cells, including Th17.1, are abundant within the
CNS,20,24 suggesting a common CXCR3-driven lymphocyte
recruitment pathway inMS.24,36,37 Other studies have also put
forward CXCR5 and its ligand CXCL13 as important con-
tributors to B-cell recruitment to the CNS.3,38 We did not
ﬁnd differences in CXCR5-expressing B cells between CNS
tissues and paired blood. Hence, the CXCR5/CXCL13 axis
is probably related to local organization rather than recruit-
ment of pathogenic B (and T) cells,39,40 in a process similar
to that in secondary lymphoid organs.41 Although these
studies indicate a role for germinal center B cells within the
CNS, little is known about which peripheral mechanisms
underlie their development and local recruitment. In mice,
it has been shown that in an autoimmune setting, IFNγ,
likely produced by activated Tfh cells, induces germinal
centers,10 which can be found in meningeal follicle-like
structures.8 In these situations, IFNγ induced B-cell–
intrinsic expression of T-bet, possibly resulting in enhanced
Ig class switching and CXCR3 expression.13,14 This points to
a central role of IFNγ-associated CXCR3+ B-cell subsets in
the meningeal process.10,12
While the inducing effects of peripheral B cells on
autoreactive Th1 cells are currently being elucidated,37 far
less is known about the impact of Th1 cells on peripheral
B-cell differentiation and function in MS patients. Therefore,
we were interested in the signals needed for B cells to differ-
entiate into T-bet+ cells and postulated that IFNγ- and IL-
21–producing Tfh1 cells in germinal centers can trigger
development of such B cells. In MS patients, B cells were
found to express higher T-bet levels under Tfh1-like culture
conditions. Furthermore, IL-21–based B- and T-cell cocul-
tures revealed that CXCR3-expressing IgG+ memory B cells
were less induced after blocking of IFNγ, which corresponds
to studies that show IFNγ regulates CXCR3 expression in
human B cells.29 Th-cell proliferation, activation, and effec-
tor memory formation were also affected in these cultures. In
line with our ﬁndings, a recent study demonstrated that
memory B cells induce proliferation of CNS-inﬁltrating Th1
cells in MS, which was inhibited after IFNγ abrogation.37
Therefore, in MS patients, peripheral interaction of CXCR3
(T-bet)+ B and IFNγ-producing Th cells probably generates
a feedforward loop, in which IFNγ enhances the potency of
B cells as antigen-presenting cells, resulting in the activation
of (IFNγ-producing) pathogenic Th cells.
Furthermore, we found that naive B cells from MS
patients developed into plasmablasts rather than IgG1-switched
memory B cells under IFNγ-only conditions. Because T-bet
mediates class-switching in murine B cells,13 we expected that
an additional signal would be required for triggering such a
mechanism in human B cells. Besides Tfh1 cells, innate TLR
signaling is also critical for naive B-cell differentiation.42
Especially pathogen-associated TLR9 and its ligand CpG-
DNA have been shown to promote the development of T-
bet+ B cells in mice.19,31,42 Correspondingly, we found that
the induction of MS-blood–derived naive B cells with both
IFNγ and CpG-DNA resulted in the development of
IgG1-switched, T-bethigh B cells during Tfh-like cultures.
Likewise, CXCR3 surface expression was more enhanced
under these conditions, reﬂecting the high CXCR3 levels on
ex vivo IgG1+ B cells. This additional effect of TLR9 signal-
ing on human T-bet+ B cells in MS links to the role of TLR9
in driving neuroinﬂammatory responses, including increased
production of chemokines in the CNS.43 Moreover,
CXCR3+IgG1+ B cells showed an enhanced transmigration
potential over brain endothelial layers, and selectively
accumulated in MS blood after natalizumab therapy. The
importance of pathogenic immune cells in contributing to
MS disease progression, such as CXCR3+ memory B cells,
has been put forward by the recurrence of often-fatal clini-
cal relapses in MS patients when discontinuing the use of
natalizumab.27,44,45 During these rebounds, Epstein–Barr
virus–infected memory B cells that have accumulated in
the blood show massive inﬂux into brain tissues of MS
patients.45 Furthermore, persistent viral infections are
suggested to sustain the development of T-bet–expressing
B cells,15 which further supports the enhanced differentia-
tion and local recruitment of CXCR3(T-bet)high memory
B cells in an organ-speciﬁc autoimmune disease such as
MS (Fig 6).
Although the exact role of (local) autoantibody pro-
duction in MS is not clear, the question of whether and
how T-bet+ B cells are involved in this process deserves
further attention. In SLE, T-bet+ B cells have autoreactive
BCRs and are prone to differentiate into IgG autoantibody–
producing plasmablasts.46 Inappropriate T-bet expression
in B cells also impaired CXCR3-mediated plasmablast
differentiation within germinal centers14 and autoanti-
body production.13 In our study, IFNγ-induced and
CpG-DNA–induced human CXCR3(T-bet)high B cells
showed increased IgG1 expression and secretion. This
strongly suggests that after preferential recruitment and
reactivation in the CNS, CXCR3(T-bet)highIgG1+ B cells
are responsible for local production of IgG1 in MS
(see Fig 6).28 Although B cells within the CNS of MS
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patients show characteristics of an antigen-driven response,
the speciﬁc antigens driving this response remain
unknown. MS disease heterogeneity is reﬂected by the
identiﬁcation of several candidate target antigens, including
nonmyelin proteins such as neuroﬁlament light and RAS
guanyl releasing protein 2 (RASGRP2).33,37 In addition to
this, increased Epstein–Barr nuclear antigen 1 (EBNA1)-
speciﬁc IgG1 titers have been found in active MS, which may
be explained by the interaction of B cells with pathogen-
associated TLR ligands and EBNA1-speciﬁc, IFNγ-producing
T cells that cross-recognize myelin antigens.47 Therefore, we
propose that the relevant antigen speciﬁcity of B cells in MS
can be found within this subset, which should be further
explored in the near future.
Taken together, not only a disrupted blood–brain bar-
rier, but also peripheral T-bet–mediated differentiation and
transmigration of IgG1+ memory populations could explain
how B cells are eventually able to mediate CNS pathology in
MS patients (see Fig 6). The relevance of T- and B-cell
interaction in tolerance breakthrough is stressed by the
ﬁnding that antigen-speciﬁc B cells are potentially 1,000
to 10,000 times better presenters of autologous peptides
to T cells than nonspeciﬁc B cells.48 We here reveal that
human CXCR3(T-bet)+ B cells are a product of T- and B-
cell interaction. Similar to SLE, such populations probably
serve as potent antigen-presenting cells in CNS-speciﬁc auto-
immune diseases such as MS.31 Anti-CD20 therapy exerts
immediate effects and is assumed to predominantly affect this
function of B cells in MS patients.35 The potential role of
CXCR3(T-bet)+ B cells as prime targets of this therapy is fur-
ther supported by their abundant CD20 expression, as shown
in the current study. The development of new targeted
strategies to inhibit T-bet function have the potential to
become a double-edged sword in MS by suppressing
pathogenic, IFNγ-producing T (Th17.1) cells together
with their counterpart CXCR3(T-bet)+ B cells. Small
molecule inhibitors of IFNγ signaling (jakinibs)49 and the
TLR/myD88 pathway50 are already used in clinics for other
inﬂammatory diseases, and are promising candidates for com-
bined suppression of IFNγ and TLR signals to control patho-
genic T-bet+ B cells in autoimmune diseases such asMS.
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